- Home
- EU vs EYPT Comparison
EU vs EYPT Comparison
Compare EU & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- EYPT
- Stock Information
- Founded
- EU 2009
- EYPT 1987
- Country
- EU United States
- EYPT United States
- Employees
- EU N/A
- EYPT N/A
- Industry
- EU Other Metals and Minerals
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- EU Basic Materials
- EYPT Industrials
- Exchange
- EU Nasdaq
- EYPT Nasdaq
- Market Cap
- EU N/A
- EYPT 579.4M
- IPO Year
- EU N/A
- EYPT 2005
- Fundamental
- Price
- EU $2.93
- EYPT $10.15
- Analyst Decision
- EU Strong Buy
- EYPT Strong Buy
- Analyst Count
- EU 1
- EYPT 8
- Target Price
- EU $2.75
- EYPT $24.75
- AVG Volume (30 Days)
- EU 3.7M
- EYPT 784.9K
- Earning Date
- EU 08-13-2025
- EYPT 08-06-2025
- Dividend Yield
- EU N/A
- EYPT N/A
- EPS Growth
- EU N/A
- EYPT N/A
- EPS
- EU N/A
- EYPT N/A
- Revenue
- EU $46,179,000.00
- EYPT $56,042,000.00
- Revenue This Year
- EU $27.46
- EYPT N/A
- Revenue Next Year
- EU $140.12
- EYPT N/A
- P/E Ratio
- EU N/A
- EYPT N/A
- Revenue Growth
- EU N/A
- EYPT 12.04
- 52 Week Low
- EU $1.01
- EYPT $3.91
- 52 Week High
- EU $4.44
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- EU 71.64
- EYPT 62.47
- Support Level
- EU $2.25
- EYPT $8.96
- Resistance Level
- EU $2.93
- EYPT $10.20
- Average True Range (ATR)
- EU 0.20
- EYPT 0.76
- MACD
- EU 0.04
- EYPT -0.03
- Stochastic Oscillator
- EU 96.81
- EYPT 62.90
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.